Vertex reports second quarter 2024 financial results

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today reported consolidated financial results for the second quarter ended june 30, 2024, and raised its full year product revenue guidance to $10.65 to $10.85 billion. “vertex delivered another strong quarter of revenue growth coupled with outstanding execution across the business, and we are increasing our full year product revenue guidance,” said reshma kewalramani, m.d., chief executive officer, and president of ver.
VRTX Ratings Summary
VRTX Quant Ranking